ABBV vs AMGN Comparison: AI Score, Valuation, Performance and Upside
Compare AbbVie and Amgen by immunology drug revenue, biosimilar exposure, post-Humira pipeline strength, dividend yield, and long-term valuation.
Use this AbbVie vs Amgen comparison to evaluate the key differences across valuation, growth, profitability, and risk before making an investment decision.
ABBV holds the edge across 3 of 5 key metrics in this comparison. ABBV has delivered stronger 1-year price return (+35.37% vs +19.75%), though AMGN has the better forward P/E setup (15.62x vs 15.63x for ABBV). On fundamentals, ABBV is growing revenue faster (12.40%), while AMGN maintains the higher operating margin (33.80%) — a classic growth-versus-profitability split. Analyst consensus implies meaningfully more upside for ABBV (+4.75%) than for AMGN (-2.64%).
| Metric | ABBV | AMGN |
|---|---|---|
| AI score | 49.8 | 47.8 |
| AI rank | #521 | #617 |
| Latest close | $253.30 | $366.05 |
| 1M return | +10.13% | +6.19% |
| 6M return | +17.19% | +6.53% |
| 1Y return | +35.37% | +19.75% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | ABBV | AMGN |
|---|---|---|
| 1Y ago | $13.29K (+32.9%) started 2025-07-23 | $11.84K (+18.4%) started 2025-07-23 |
| 5Y ago | $29.01K (+190.1%) started 2021-07-26 | $19.44K (+94.4%) started 2021-07-26 |
| 10Y ago | $89.25K (+792.5%) started 2016-07-25 | $39.04K (+290.4%) started 2016-07-25 |
Hypothetical — past performance does not guarantee future results.
| Metric | ABBV | AMGN |
|---|---|---|
| Market cap | $449.63B | $197.69B |
| Trailing P/E | 124.75 | 25.51 |
| Forward P/E | 15.63 | 15.62 |
| Price/Sales | 5.85 | 4.57 |
| EV/Revenue | 8.17 | 6.53 |
| Analyst target | $266.57 | $356.62 |
| Target upside | +4.75% | -2.64% |
| Metric | ABBV | AMGN |
|---|---|---|
| Revenue growth | 12.40% | 5.80% |
| Earnings growth | -46.20% | 4.40% |
| EPS growth | -46.20% | +4.40% |
| FCF margin | +33.13% | +19.98% |
| Operating margin | 32.16% | 33.80% |
| Profit margin | 5.79% | 20.96% |
| ROIC proxy | 6225.00% | 101.32% |
| Return on equity | 6225.00% | 101.32% |
| Dividend yield | 2.72% | 2.75% |
| Beta | 0.28 | 0.40 |
| Debt/equity | 4789.60 | 623.75 |
| Current ratio | 0.80 | 1.26 |
| Quick ratio | 0.52 | 0.85 |
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | ABBV | AMGN |
|---|---|---|---|
| 1Y | Growth | +32.93% | +18.38% |
| CAGR | +33.02% | +18.43% | |
| Sharpe ratio | 1.06 | 0.59 | |
| Max drawdown | 19.23% | 16.57% | |
| Max daily drop | 5.20% | 5.14% | |
| Max wkly drop | 8.49% | 8.70% | |
| 5Y | Growth | +148.44% | +69.73% |
| CAGR | +20.00% | +11.18% | |
| Sharpe ratio | 0.71 | 0.37 | |
| Max drawdown | 21.92% | 24.86% | |
| Max daily drop | 12.57% | 7.14% | |
| Max wkly drop | 17.30% | 12.81% | |
| 10Y | Growth | +470.87% | +187.48% |
| CAGR | +19.04% | +11.15% | |
| Sharpe ratio | 0.63 | 0.37 | |
| Max drawdown | 45.09% | 24.86% | |
| Max daily drop | 16.25% | 9.58% | |
| Max wkly drop | 19.39% | 15.79% |
| Category | ABBV | AMGN |
|---|---|---|
| Company | ABBV | AMGN |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - General | Drug Manufacturers - General |
| Core business | N/A | N/A |
| Investor focus | N/A | N/A |
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.